Insights
More Articles
- EU approves anemia drug Reblozyl
- Takeda, Carmine partner for $1B gene therapies deal
- Flu strain with pandemic potential discovered in China
- Japanese regulators approve two anemia drugs
- Marginal zone lymphoma drug gets FDA fast-track tag
EU approves anemia drug Reblozyl
The EU has approved Reblozyl, an erythroid maturation agent that treats anemia in patients with a rare blood cancer. The drug is manufactured by Bristol-Myers Squibb and was under development by Celegne before it merged with BMS. PMLive (UK) (6/29)
Read full article now.
×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!